Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS30085858HIVENSG00000179603.19protein_codingGRM8NoNo2918O00222
TVIS30067895HIVENSG00000179603.19protein_codingGRM8NoNo2918O00222
TVIS30067896HIVENSG00000179603.19protein_codingGRM8NoNo2918O00222
TVIS30067897HIVENSG00000179603.19protein_codingGRM8NoNo2918O00222
TVIS30067898HIVENSG00000179603.19protein_codingGRM8NoNo2918O00222
TVIS20001916HPVENSG00000179603.19protein_codingGRM8NoNo2918O00222
TVIS20012293HPVENSG00000179603.19protein_codingGRM8NoNo2918O00222
TVIS20011237HPVENSG00000179603.19protein_codingGRM8NoNo2918O00222
TVIS20013494HPVENSG00000179603.19protein_codingGRM8NoNo2918O00222
TVIS20061439HPVENSG00000179603.19protein_codingGRM8NoNo2918O00222
TCGA Plot Options
Drug Information
GeneGRM8
DrugBank IDDB00142
Drug NameGlutamic acid
Target IDBE0000835
UniProt IDO00222
Regulation Type
PubMed IDs17360958; 16957773
CitationsSuzuki G, Kimura T, Satow A, Kaneko N, Fukuda J, Hikichi H, Sakai N, Maehara S, Kawagoe-Takaki H, Hata M, Azuma T, Ito S, Kawamoto H, Ohta H: Pharmacological characterization of a new, orally active and potent allosteric metabotropic glutamate receptor 1 antagonist, 4-[1-(2-fluoropyridin-3-yl)-5-methyl-1H-1,2,3-triazol-4-yl]-N-isopropyl-N-methyl- 3,6-dihydropyridine-1(2H)-carboxamide (FTIDC). J Pharmacol Exp Ther. 2007 Jun;321(3):1144-53. Epub 2007 Mar 14.@@Morimoto R, Uehara S, Yatsushiro S, Juge N, Hua Z, Senoh S, Echigo N, Hayashi M, Mizoguchi T, Ninomiya T, Udagawa N, Omote H, Yamamoto A, Edwards RH, Moriyama Y: Secretion of L-glutamate from osteoclasts through transcytosis. EMBO J. 2006 Sep 20;25(18):4175-86. Epub 2006 Sep 7.
GroupsApproved; Nutraceutical
Direct ClassificationGlutamic acid and derivatives
SMILESN[C@@H](CCC(O)=O)C(O)=O
PathwaysHistidinemia; Guanidinoacetate Methyltransferase Deficiency (GAMT Deficiency); 3-Methylglutaconic Aciduria Type I; beta-Ketothiolase Deficiency; Purine Nucleoside Phosphorylase Deficiency; Tyrosine Metabolism; Ketoprofen Action Pathway; Glutamate Metabolism; Argininosuccinic Aciduria; Salla Disease/Infantile Sialic Acid Storage Disease; Tyrosinemia Type I; Hyperinsulinism-Hyperammonemia Syndrome; 2-Methyl-3-hydroxybutryl-CoA Dehydrogenase Deficiency; Glutaric Aciduria Type I; Propanoate Metabolism; Celecoxib Action Pathway; Glycine and Serine Metabolism; Suprofen Action Pathway; Indomethacin Action Pathway; Carbamoyl Phosphate Synthetase Deficiency; Sialuria or French Type Sialuria; Ibuprofen Action Pathway; Saccharopinuria/Hyperlysinemia II; Histidine Metabolism; Arginine and Proline Metabolism; Purine Metabolism; Diflunisal Action Pathway; Etodolac Action Pathway; Ammonia Recycling
PharmGKBPA449776
ChEMBLCHEMBL575060